Glucagon
- Generic Name
- Glucagon
- Brand Names
- Baqsimi, Glucagen, Gvoke, Ogluo
- Drug Type
- Biotech
- CAS Number
- 16941-32-5
- Unique Ingredient Identifier
- 76LA80IG2G
- Background
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.
Glucagon was granted FDA approval on 14 November 1960.
- Indication
Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.
- Associated Conditions
- Severe Hypoglycemia
Three Way Crossover Closed Loop Study With Xeris Glucagon
- Conditions
- Type1diabetes
- Interventions
- Device: Artificial Pancreas Controller in Predictive Low Glucose Suspend ModeDevice: Artificial Pancreas Controller in Dual Hormone ModeDevice: Artificial Pancreas Controller in Single Hormone Mode
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 23
- Registration Number
- NCT03424044
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 75
- Registration Number
- NCT03421379
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
🇯🇵For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Tokyo, Japan
A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus
- Conditions
- HypoglycemiaDiabetes Mellitus, Type 1
- Interventions
- Drug: Intramuscular Glucagon
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT03339453
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany
Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia
- Conditions
- Post-bariatric Hypoglycemia
- Interventions
- Device: Closed loop glucagon pump
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- Joslin Diabetes Center
- Target Recruit Count
- 18
- Registration Number
- NCT03255629
- Locations
- 🇺🇸
Joslin Diabetes Center, Boston, Massachusetts, United States
Liver Glycogen and Hypoglycemia in Humans
- Conditions
- Hypoglycemia; Iatrogenic
- Interventions
- Drug: SalineDrug: Low FructoseDrug: High Fructose
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Jason Winnick
- Target Recruit Count
- 40
- Registration Number
- NCT03241706
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-07-13
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT03217175
- Locations
- 🇺🇸
MGH Diabetes Research Center, Boston, Massachusetts, United States
Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- AdventHealth Translational Research Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03139305
- Locations
- 🇺🇸
Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States
Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT03091673
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
Characterization of Metabolic and Brain Effects of Rising Glucagon During an Oral Glucose Challenge
- Conditions
- Metabolic SyndromeDiabetes
- Interventions
- Drug: Intravenous saline
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 32
- Registration Number
- NCT03061227
- Locations
- 🇩🇪
University Hospital Tübingen, Tübingen, Germany
Feasibility Trial Testing the Bionic Pancreas With ZP4207
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: ZP4207 (dasiglucagon)Device: iPhone-based bionic pancreasDevice: iLet-based bionic pancreas
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 13
- Registration Number
- NCT02971228
- Locations
- 🇺🇸
MGH Diabetes Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.